Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting

Overview of attention for article published in Frontiers in oncology, June 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 6 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 3 publications that cite this research output.

3

The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.

Efficacy and safety of anlotinib as maintenance therapy in patients with advanced non-small cell lung cancer achieving SD post first-line chemotherapy combined with immunotherapy

Article in Journal of Chemotherapy (September 2024)

Crizotinib inhibits the metabolism of tramadol by non-competitive suppressing the activities of CYP2D1 and CYP3A2

Article in PeerJ (May 2024)

Efficacy and Safety of Anlotinib in EGFR-Positive Patients with Advanced Lung Adenocarcinoma Compared with Chemotherapy: A Retrospective Study

Article in Technology in Cancer Research & Treatment (January 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.